Personas / Equipo Humano

Alicia Castañeda Heredia

Buscador de publicaciones

Publicaciones

  • Santa-María López V, Felip-Badia A, Marina Caballero Bellón, Sanchez-Sierra N, Castañeda-Heredia A, Garraus-Oneca M, Gorostegui M, Simão-Rafael M, Muñoz JP, Pérez-Somarriba M, Mañe S, Planells MC, Pérez-Jaume S and Mora J.

    Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio-Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse

    PEDIATRIC BLOOD & CANCER . : .

    [doi:10.1002/1545-5017.70105]

  • Carceller, F, Bautista, F, Van Tinteren, H, Castañeda-Heredia A, Surun, A, Wasti, A, Revon-Rivière, G, Bergamaschi, L, Cortés, M, Hladun-Alvaro, R, Jiménez, I, Giraudi, C, Millen, G, Campbell-Hewson, Q, Juan-Ribelles, A, Van der Lugt, J, Amoroso, L, Bertorello, N, Hargrave, D, Vega-Piris, L, Fagioli, F, Haupt, R, Zwaan, CM, Cañete, A, Morlandj, B, Cerauloi, A, Casanova, M, Verschuur, A, André, N, Aerts, I, Doz, F, Pearson, ADJ, Marshall, LV, Vassal, G, Kearnsj, P, Geoerger, B and Moreno, L.

    Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study

    EUROPEAN JOURNAL OF CANCER . 227: .

    [doi:10.1016/j.ejca.2025.115627]

  • Sentís I, Melero JL, Cebrià A, Grzelak M, Soto M, Michel A, Rovira Q, Rodriguez-Hernandez CJ, Caratù G, Urpi A, Sauvage C, Mendizabal-Sasieta A, Maspero D, Lavarino C, Pascual-Reguant A, Castañeda-Heredia A, Muñoz Perez JP, Mora J, Harari A, Nieto JC, Avgustinova A and Heyn H.

    Spatiotemporal T-cell tracking for personalized T-cell receptor T-cell therapy designs in childhood cancer

    ANNALS OF ONCOLOGY . 36(9): 1096-1106.

    [doi:10.1016/j.annonc.2025.05.530]

  • Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J.

    Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes

    PEDIATRIC BLOOD & CANCER . 71(10): . Nº de citas: 1

    [doi:10.1002/pbc.31221]

  • Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.

    Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects

    Frontiers in Oncology . 14: 1380917-1380917.

    [doi:10.3389/fonc.2024.1380917]

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): . Nº de citas: 2

    [doi:10.3390/cancers16091735]

  • Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.

    Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

    Cancers . 15(19): . Nº de citas: 20

    [doi:10.3390/cancers15194837]

  • Gomez-Gonzalez S, Llano-Viles J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C.

    EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping

    iScience . 26(9): 107598-107598. Nº de citas: 1

    [doi:10.1016/j.isci.2023.107598]

  • Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J.

    Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

    Frontiers in Oncology . 13: 1164949-1164949. Nº de citas: 11

    [doi:10.3389/fonc.2023.1164949]

  • Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.

    Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report

    Cancers . 15(9): . Nº de citas: 20

    [doi:10.3390/cancers15092535]